SCHEMBL4023745

SCHEMBL4023745

O=C(NC1CCN(c2nccc3cc(Cl)ccc23)CC1)c1ccc(F)cc1F

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.54
CCNE1 P24864 4/20 0.46
CDK2 P24941 4/20 0.46
HPGD P15428 1/20 0.45
CNR2 P34972 1/20 0.43
DRD2 P14416 1/20 0.43
HTR2A P28223 1/20 0.43
DRD3 P35462 1/20 0.43
GPR119 Q8TDV5 3/20 0.43
KCNH2 Q12809 2/20 0.43
CCR3 P51677 1/20 0.43
PAK1 Q13153 3/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAP3K5 Q99683 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019718 0.93 CNR1 (0.47) CNR1CCNE1CDK2HPGDCNR2
SCHEMBL4018789 0.90 DRD2 (0.44) CNR1CCNE1CDK2HPGDCNR2
SCHEMBL4023469 0.90 DRD2 (0.44) CNR1CCNE1CDK2CNR2DRD2
SCHEMBL4583304 0.90 CNR1 (0.53) CNR1CCNE1CDK2CNR2CCR3
SCHEMBL4022674 0.89 CCNE1 (0.45) CNR1CCNE1CDK2CNR2DRD2
SCHEMBL4016296 0.87 PAK1 (0.56) CNR1CCNE1CDK2CNR2DRD2
SCHEMBL4017530 0.86 CNR1 (0.46) CNR1CCNE1CDK2CNR2DRD2
SCHEMBL4016437 0.85 CCNE1 (0.49) CNR1CCNE1CDK2CNR2DRD2
SCHEMBL4016285 0.85 CNR1 (0.58) CNR1HPGDCNR2GPR119KCNH2
SCHEMBL4022758 0.85 CNR1 (0.49) CNR1CCNE1CDK2HPGDCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066654-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS Bayer Schering Pharma AG (DE) 2009-06-10 EP claimed
US-20080125463-A1 N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators BAYER SCHERING PHARMA AG (DE) 2008-05-29 US claimed
EP-1903038-A1 N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators Bayer Schering Pharma Aktiengesellschaft (DE) 2008-03-26 EP claimed
WO-2008028691-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO claimed
EP-2066654-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS Bayer Schering Pharma AG (DE) 2009-06-10 EP disclosed
US-20080125463-A1 N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators BAYER SCHERING PHARMA AG (DE) 2008-05-29 US disclosed
EP-1903038-A1 N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators Bayer Schering Pharma Aktiengesellschaft (DE) 2008-03-26 EP disclosed
WO-2008028691-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125463-A1 N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators PTGER2, PTGER1, PTGDR2 CNR1 23/4885CCNE1 3709/4885CDK2 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.